Treatment of abdominal symptoms in non-complicated

The effect of mesalazine in comparison with placebo in uncomplicated diverticulosis with abdominal symptoms

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201606237080N4

Enrollment

120

Registered

2016-07-04

Start date

2016-06-30

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diverticulosis. Diverticular disease of intestine, Diverticular disease of large intestine without perforation or abscess, Diverticular disease of both small and large intestine without perforation or abscess, Diverticular disease of intestine, part unspecified, without

Interventions

Intervention 1: 3 Pills of mesalazine 500 mg in a day (1.5 gr daily) for 1 week in each month, for 3 months. Intervention 2: 3 pills of placebo, daily, for 1 week in each month, for 3 months.

Treatment - Drugs

3 Pills of mesalazine 500 mg in a day (1.5 gr daily) for 1 week in each month, for 3 months.

3 pills of placebo, daily, for 1 week in each month, for 3 months.

Eligibility

Sex/Gender

All

Age

40 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: the patients between 40 to 70 years old that have chronic abdominal pain and colonoscopy or barium enema are done for them and based on clinical symptoms and colonoscopy and radiology; the diagnosis of diverticulosis is arisen for them. Exclusion criteria: age below 40 and above 70; patients with history of abdominal surgery; musculoskeletal disease; spinal disorders; gallbladder stone; renal stone; bowel motility disease and inflammatory bowel disease.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Bloat. Timepoint: At the start of intervention, 1 month later, 2 months later, 3 months later. Method of measurement: questionnaire.;Mucus discharge. Timepoint: At the start of intervention, 1 month later, 2 months later, 3 months later. Method of measurement: Number of defecation in a week.;Constipation. Timepoint: At the start of intervention, 1 month later, 2 months later, 3 months later. Method of measurement: Number of defecation in a week.;Abdominal pain. Timepoint: At the start of intervention, 1 month later, 2 months later, 3 months later. Method of measurement: VAS( score 0 to 10).	—

Measure

Time frame

Bloat. Timepoint: At the start of intervention, 1 month later, 2 months later, 3 months later. Method of measurement: questionnaire.;Mucus discharge. Timepoint: At the start of intervention, 1 month later, 2 months later, 3 months later. Method of measurement: Number of defecation in a week.;Constipation. Timepoint: At the start of intervention, 1 month later, 2 months later, 3 months later. Method of measurement: Number of defecation in a week.;Abdominal pain. Timepoint: At the start of intervention, 1 month later, 2 months later, 3 months later. Method of measurement: VAS( score 0 to 10).

—

Secondary

Measure	Time frame
Diverticulitis. Timepoint: At the start of the intervention, after 2 month of treatment. Method of measurement: Clinical symptoms and signs and CT scan.;Bleeding. Timepoint: At the start of the intervention, after 2 month of treatment. Method of measurement: See bleeding.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaede Abdinzade

Babol University of Medical Sciences

abedinzadeh.ma@yahoo.com+98 11 3219 7667

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026